Suzhou Zelgen Biopharmaceuticals
As of the edition of 20 October 2026, Suzhou Zelgen Biopharmaceuticals runs 9 drugs, 2 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 5 |
| Status not established | 2 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Toripalimab | Ends 2035 (computed from the first US licence) | 2 |
| Sugemalimab | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CTLA4 Cytotoxic T-lymphocyte protein 4 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Suzhou Zelgen Biopharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 17 trials led
- Lungs and airways: 7 trials led
- Digestive system: 2 trials led